Products Zostavax
Zostavax Phase 3 Completed 0 watching 0 views this week๐ Rising Prevention of : Herpes-Zoster
Prevention of : Herpes-Zoster
Oct 26, 2007 โ Jun 3, 2009
About Zostavax Zostavax is a phase 3 stage product being developed by Merck for Prevention of : Herpes-Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT00561080. Target conditions include Prevention of : Herpes-Zoster.
Clinical Trials (3) NCT ID Phase Status Start Completion Indication NCT01391546 Phase 3 Completed Jun 20, 2011 Oct 15, 2012 Herpes Zoster NCT01328548 Pre-clinical Completed May 1, 2011 Mar 1, 2015 Immune System Diseases NCT00561080 Phase 3 Completed Oct 26, 2007 Jun 3, 2009 Prevention of : Herpes-Zoster
Product Company Stage Hype Score edoxaban + enoxaparin sodium Daiichi Sankyo Phase 3 Mifepristone Eli Lilly Phase 2 EXANTA AstraZeneca Phase 2 Risk of low dose aspirin discontinuation AstraZeneca Pre-clinical DAPA/MET XR + DAPA + MET XR AstraZeneca Phase 3 Esomeprazole + Placebo AstraZeneca Phase 3 PCV15 Merck Pre-clinical Raltegravir Merck Approved RotaTeq (V260) + IPV Merck Phase 3 V501 Merck Phase 3 V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 Merck Phase 3 Letermovir + Placebo Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Enteric-coated mycophenolate sodium Novartis Phase 3 Meningococcal C conjugate vaccine Novartis Approved rMenB+OMV NZ Novartis Phase 3 Enteric-Coated Mycophenolate Sodium Novartis Phase 3 Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml Novartis Phase 3 Meningococcal C Conjugate Vaccine Novartis Phase 3 MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine) Novartis Phase 2
Other Products from Merck